CARLSBAD, Calif., Feb. 28 /PRNewswire-FirstCall/ -- The Immune Response
Corporation (OTC Bulletin Board: IMRP) today announced that it has extended
to March 30, 2007 the expiration date of the 6,000,000 second tranche
warrants issued in connection with its 2006 private placement offering. The
second tranche warrants previously were set to expire March 1, 2007. If
fully exercised, the second tranche warrants, which first became
exercisable on October 16, 2006, could provide the Company with additional
gross proceeds of $12,000,000.
Before the Company's December 2006 1-for-100 reverse stock split, these
warrants had been exercisable for 600,000,000 shares of common stock.
About The Immune Response Corporation
The Immune Response Corporation (OTC Bulletin Board: IMRP, formerly
IMNR) is an immuno-pharmaceutical company focused on developing products to
treat autoimmune and infectious diseases. The Company's lead immune-based
therapeutic product candidates are NeuroVax(TM) for the treatment of MS and
REMUNE(R) and IR103 for the treatment of HIV infection. These therapies are
in Phase II clinical development and are designed to stimulate disease
pathogen-specific immune responses aimed at slowing or halting the rate of
disease progression.
NeuroVax(TM), which is based on the Company's patented T-cell receptor
(TCR) peptide vaccine technology, has shown potential clinical value in the
treatment of relapsing forms of MS. NeuroVax(TM) has been shown to
stimulate strong, disease-specific cell-mediated immunity in nearly all
patients treated and appears to work by enhancing levels of FOXP3+ Treg
cells that are able to down regulate the activity of pathogenic T-cells
that cause MS. Increasing scientific findings have associated diminished
levels of FOXP3+ Treg cell responses with the pathogenesis and progression
of MS and other autoimmune diseases such as rheumatoid arthritis (RA),
psoriasis and Crohn's disease. In addition to MS, the Company has open
Investigational New Drug Applications (IND) with the FDA for clinical
evaluation of TCR peptide-based immune-based therapies for RA and
psoriasis.
REMUNE(R) and IR103 are based on the Company's patented,
whole-inactivated virus technology, co-invented by Dr. Jonas Salk and
indicated to be safe and immunogenic in extensive clinical studies of
REMUNE(R), the Company's first generation HIV product candidate. IR103 is a
second-generation formulation that combines its whole-inactivated antigen
with a synthetic Toll-like receptor (TLR-9) agonist designed to create
enhanced HIV-specific immune responses. The Company is currently testing
REMUNE(R) and IR103 in two Phase II clinical studies as a first-line
treatment for drug-naive HIV-infected individuals not yet eligible for
antiretroviral therapy according to current medical guidelines.
NeuroVax(TM), REMUNE(R) and IR103 are in clinical development by The
Immune Response Corporation and are not approved by any regulatory agencies
in any country at this time. Please visit The Immune Response Corporation
at http://www.imnr.com for additional information.
This news release contains forward-looking statements. Forward-looking
statements are often signaled by forms of words such as should, could,
will, might, plan, projection, forecast, expect, guidance, potential and
developing. Actual results could vary materially from those expected due to
a variety of risk factors, including whether the Company will continue as a
going concern and successfully raise proceeds from financing activities
sufficient to fund operations and additional clinical trials of
NeuroVax(TM), REMUNE(R) or IR103, the uncertainty of successful completion
of any such clinical trials, the fact that the Company has not succeeded in
commercializing any drug, the risk that NeuroVax(TM), REMUNE(R) or IR103
might not prove to be effective as either a therapeutic or preventive
vaccine, whether future trials will be conducted and whether the results of
such trials will coincide with the results of NeuroVax(TM), REMUNE(R) or
IR103 in preclinical trials and/or earlier clinical trials. A more
extensive set of risks is set forth in The Immune Response Corporation's
SEC filings including, but not limited to, its Annual Report on Form 10-K
for the year ended December 31, 2005, and its subsequent Quarterly Reports
filed on Form 10-Q. The Company undertakes no obligation to update the
results of these forward-looking statements to reflect events or
circumstances after today or to reflect the occurrence of unanticipated
events.
REMUNE(R) is a registered trademark of The Immune Response Corporation.
NeuroVax(TM) is a trademark of The Immune Response Corporation.
MEDIA CONTACT:
Rachel Kessler
Chamberlain Communications Group Inc.
(212) 389-9155
rkessler@chamberlainpr.com
INVESTOR CONTACTS:
Robert Giordano
ROI Associates
(212) 495-0201
rgiordano@roiny.com
Gene Marbach
Makovsky & Company
(212) 508-9645
gmarbach@makovsky.com
COMPANY CONTACT:
Michael K. Green, COO
The Immune Response Corporation
(760) 431-7080
info@imnr.com
SOURCE The Immune Response Corporation
 back to top
Related links:
http://www.imnr.com
CONTACT:
Media, Rachel Kessler of Chamberlain
Communications Group Inc., +1-212-389-9155,
rkessler@chamberlainpr.com, for The Immune Response Corporation;
or Investors, Robert Giordano of ROI Associates, +1-212-495-0201,
rgiordano@roiny.com; or Gene Marbach of Makovsky & Company,
+1-212-508-9645, gmarbach@makovsky.com, both for The Immune
Response Corporation; or Michael K. Green, COO of The Immune
Response Corporation, +1-760-431-7080, info@imnr.com
|
